Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade

Targeted radionuclide therapy plays an increasingly important role in managing endocrine-related tumors and significantly advances the therapeutic landscape for patients with these diseases. With increasing FDA-approved therapies and advances in the field, come an increased knowledge of the potentia...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 14; p. 1187870
Main Authors Al-Toubah, Taymeyah, Strosberg, Jonathan, Hallanger-Johnson, Julie, El-Haddad, Ghassan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 20.11.2023
Subjects
endocrine
Endocrine Gland Neoplasms - drug therapy
Endocrine Gland Neoplasms - radiotherapy
Endocrinology
Humans
neuroendocrine
paraganglioma
pheochromocytoma
Radioisotopes - therapeutic use
radiopharmaceutical
pheochromocytoma
neuroendocrine
radiopharmaceutical
endocrine
paraganglioma
Online AccessGet full text

Cover

More Information
Summary:Targeted radionuclide therapy plays an increasingly important role in managing endocrine-related tumors and significantly advances the therapeutic landscape for patients with these diseases. With increasing FDA-approved therapies and advances in the field, come an increased knowledge of the potential for long-term toxicities associated with these therapies and the field must develop new strategies to increase potency and efficacy while individualizing the selection of patients to those most likely to respond to treatment. Novel agents and modalities of therapy are also being explored. This review will discuss the current landscape and describe the avenues for growth in the field currently being explored.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Elcin Zan, New York University, United States
Reviewed by: Timon Vandamme, Antwerp University Hospital, Belgium; Murat Fani Bozkurt, Hacettepe University, Türkiye; Mark Kidd, Wren Laboratories, United States
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2023.1187870